Medoxycin

Oxytocin

Induction & augmentation of labour; controls postpartum bleeding & uterine hypotonicity in the 3rd stage of labour, & promotes lactation in cases of faulty milk ejection; missed abortions.

IV Induction or augmentation of labour 5 u in 500 mL of physiological electrolyte soln eg, 0.9% NaCl by slow IV infusion; may be given by infusion pump if soln is more concentrated. Postpartum haemorrhage 5 u slow IV inj; may be followed by 5-20 u in 500 mL of non-hydrating diluent by IV infusion in severe cases.

Hypersensitivity.

Do not give where spontaneous labour or vag delivery can harm either the mother or the fetus, including significant cephalopelvic disproportion or unfavourable presentation of the fetus, placenta praevia or vasa praevia cord presentation or prolapse, mechanical obstruction to delivery, fetal distress or hypertonic uterine contractions. Do not use where there is a predisposition to uterine rupture, ie multiple pregnancy or high parity, polyhydramnios, or presence of a uterine scar from previous caesarean section. Do not use for prolonged periods in resistant uterine inertia, severe pre-eclampsia or severe CV disorders. Caution in use for induction or enhancement of labour in borderline cephalopelvic disproportion, less severe degrees of CV disease & in patients >35 yr or w/ other risk factors. Monitor fetal heart rate & uterine motility to adjust dosage according to individual response; give by IV infusion. Discontinue immediately if fetal distress or uterine hyperactivity occur. Avoid over-vigorous labour in fetal death in utero, or in meconium-stained amniotic fluid. Risk of water intoxication in high doses administered over a long time.

Violent uterine contraction, leading to uterine rupture & extensive laceration of the soft tissue, fetal bradycardia, fetal arrhythmias, & fetal asphyxiation, & possible fetal or maternal death in high doses or when administered to hypersensitive patients. Maternal death due to severe HTN & subarachnoid haemorrhage. Postpartum haemorrhage & fatal afibrinogenaemia. Water retention leading to hyponatremia & intoxication, w/ pulmonary oedema, convulsions, coma, & death when given IV over prolonged periods. Vasopressin-like activity may occur. Anaphylactic & other hypersensitivity reactions, cardiac arrythmias, pelvic haematomas, nausea & vomiting. Acute transient hypotension, flushing & reflex tachycardia in rapid IV inj. Neonatal jaundice & retinal haemorrhage. Nasal irritation, rhinorrhoea, lachrymation, uterine bleeding, & violent uterine contractions following intranasal administration.

Drugs Acting on the Uterus

H01BB02 - oxytocin ; Belongs to the class of oxytocin and analogues. Used in posterior pituitary lobe hormone preparations.